ABUSE-PROOFED ORAL DOSAGE FORM
First Claim
1. An abuse-proofed oral dosage form with controlled opioid release for once daily administration, comprising at least one opioid with potential for abuse (A) and/or one of the physiologically acceptable compounds or derivatives thereof, at least one synthetic or natural polymer (C), optionally delayed-release auxiliary substances, optionally physiologically acceptable auxiliary substances (B), optionally a wax (D) and optionally at least one delayed-release coating, wherein the at least one opioid with potential for abuse (A) is selected from the group consisting of oxymorphone and physiologically acceptable compounds and derivatives thereof, and wherein the dosage form exhibits a breaking strength of at least 500 N.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to an abuse-proofed, oral dosage form with controlled opioid-release for once daily administration, characterised in that it comprises at least one opioid with potential for abuse (A), at least one synthetic or natural polymer (C), optionally delayed-release matrix auxiliary substances, physiologically acceptable auxiliary substances (B), optionally a wax (D) and optionally at least one delayed-release coating, component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N.
37 Citations
23 Claims
- 1. An abuse-proofed oral dosage form with controlled opioid release for once daily administration, comprising at least one opioid with potential for abuse (A) and/or one of the physiologically acceptable compounds or derivatives thereof, at least one synthetic or natural polymer (C), optionally delayed-release auxiliary substances, optionally physiologically acceptable auxiliary substances (B), optionally a wax (D) and optionally at least one delayed-release coating, wherein the at least one opioid with potential for abuse (A) is selected from the group consisting of oxymorphone and physiologically acceptable compounds and derivatives thereof, and wherein the dosage form exhibits a breaking strength of at least 500 N.
Specification